IRulya Therapeutics (QNCX) Stock Analysis & Price (Updated Oct 15, 2026, 4:00 PM ET)
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $33.23, +10.77% vs the prior close of $30.00.
- Volume 9.00K shares, 0.3x its 50-day average (light).
- New SEC filings: SCHEDULE 13G (Oct 14, 2026), SCHEDULE 13G (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
QNCX jumps 10.8% to $33.23, a 1-month high. Closed at $33.23, +10.77% vs the prior close of $30.00. Day range $28.99–$33.71, opened at $28.99.
QNCX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — QNCX jumps 10.8% to $33.23, a 1-month high
- Closed at $33.23, +10.77% vs the prior close of $30.00. Day range $28.99–$33.71, opened at $28.99.
- Volume was 9.00K shares, 0.3x its 50-day average of 28.79K — lighter than usual.
- Price is +7.9% vs its 50-day average ($30.79) and -61.0% vs its 200-day average ($85.12).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.3% below the 52-week high.
Oct 14, 2026 — QNCX jumps 7.6% to $30.00
- Closed at $30.00, +7.64% vs the prior close of $27.87. Day range $26.72–$30.23, opened at $26.72.
- Volume was 26.90K shares, 0.9x its 50-day average of 28.78K.
- Price is -2.3% vs its 50-day average ($30.70) and -66.0% vs its 200-day average ($88.35).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.7% below the 52-week high.
Oct 13, 2026 — QNCX slides 14.0% to $27.87 on 3.0x normal volume
- Closed at $27.87, -13.98% vs the prior close of $32.40. Day range $25.13–$30.80, opened at $28.51.
- Volume was 84.30K shares, 3.0x its 50-day average of 28.18K — unusually heavy trading.
- Price is -9.1% vs its 50-day average ($30.65) and -69.6% vs its 200-day average ($91.76).
- 52-week range $15.10–$910.00; today's close sits at 1% of that range, 96.9% below the 52-week high.
Oct 12, 2026 — QNCX rises 2.1% to $32.40, a 1-month high on 2.8x normal volume
- Closed at $32.40, +2.11% vs the prior close of $31.73. Day range $26.50–$32.60, opened at $29.51.
- Volume was 76.90K shares, 2.8x its 50-day average of 27.34K — unusually heavy trading.
- Price is +5.9% vs its 50-day average ($30.59) and -66.0% vs its 200-day average ($95.28).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.4% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — QNCX jumps 8.1% to $31.73, a 1-month high on 5.4x normal volume
- Closed at $31.73, +8.07% vs the prior close of $29.36. Day range $29.84–$37.00, opened at $30.50.
- Volume was 138.70K shares, 5.4x its 50-day average of 25.75K — unusually heavy trading.
- Price is +4.3% vs its 50-day average ($30.41) and -67.9% vs its 200-day average ($98.79).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.5% below the 52-week high.
- SEC filings that day: 8-K.
Oct 8, 2026 — QNCX jumps 9.9% to $29.36
- Closed at $29.36, +9.88% vs the prior close of $26.72. Day range $26.65–$29.80, opened at $27.09.
- Volume was 31.90K shares, 1.2x its 50-day average of 26.72K.
- Price is -2.9% vs its 50-day average ($30.24) and -71.3% vs its 200-day average ($102.28).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.8% below the 52-week high.
Oct 7, 2026 — QNCX dips 0.3% to $26.72, a 1-month low, 6 down days in a row
- Closed at $26.72, -0.34% vs the prior close of $26.81. Day range $26.72–$27.95, opened at $26.74.
- Volume was 12.70K shares, 0.5x its 50-day average of 27.21K — lighter than usual.
- Price is -11.2% vs its 50-day average ($30.09) and -74.7% vs its 200-day average ($105.71).
- 52-week range $15.10–$910.00; today's close sits at 1% of that range, 97.1% below the 52-week high.
- That makes 6 straight losses.
Oct 6, 2026 — QNCX slides 4.6% to $26.81, a 1-month low, 5 down days in a row
- Closed at $26.81, -4.59% vs the prior close of $28.10. Day range $26.81–$28.15, opened at $27.68.
- Volume was 27.80K shares, 1.0x its 50-day average of 27.02K.
- Price is -10.5% vs its 50-day average ($29.94) and -75.4% vs its 200-day average ($109.05).
- 52-week range $15.10–$910.00; today's close sits at 1% of that range, 97.1% below the 52-week high.
- That makes 5 straight losses.
- SEC filings that day: 8-K.
Oct 5, 2026 — QNCX slides 3.8% to $28.10, 4 down days in a row
- Closed at $28.10, -3.77% vs the prior close of $29.20. Day range $28.00–$29.78, opened at $29.00.
- Volume was 22.10K shares, 0.8x its 50-day average of 26.88K.
- Price is -5.6% vs its 50-day average ($29.76) and -75.1% vs its 200-day average ($112.64).
- 52-week range $15.10–$910.00; today's close sits at 1% of that range, 96.9% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — QNCX slides 4.8% to $29.20 on 2.6x normal volume
- Closed at $29.20, -4.82% vs the prior close of $30.68. Day range $29.20–$31.06, opened at $30.20.
- Volume was 68.40K shares, 2.6x its 50-day average of 25.94K — unusually heavy trading.
- Price is -1.2% vs its 50-day average ($29.56) and -74.9% vs its 200-day average ($116.20).
- 52-week range $15.10–$910.00; today's close sits at 2% of that range, 96.8% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
QNCX latest news & SEC filings
Every SEC filing by or about QNCX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Oct 8, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Oct 2, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Oct 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 25, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 24, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade QNCX
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: Feb 12, 2026, Nov 12, 2025, Aug 11, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.23% (largest 14.0%). That is a volatile stock.
- Liquidity: about 35.40K shares (≈$1.18M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $33.23 vs a range of $15.10–$910.00 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Jun 30, 2026, 1:10 on Apr 13, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Luca Benatti sold 50,000 shares on Dec 26, 2025.
- Latest filings: 8-K Oct 9, 2026; 8-K Oct 6, 2026; 8-K Oct 2, 2026.
- Share count: 1.02M shares outstanding (Aug 7, 2026), -98.1% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
QNCX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 28.99 | 33.71 | 28.99 | 33.23 | 9.00K |
| Oct 14, 2026 | 26.72 | 30.23 | 26.72 | 30.00 | 26.90K |
| Oct 13, 2026 | 28.51 | 30.80 | 25.13 | 27.87 | 84.30K |
| Oct 12, 2026 | 29.51 | 32.60 | 26.50 | 32.40 | 76.90K |
| Oct 9, 2026 | 30.50 | 37.00 | 29.84 | 31.73 | 138.70K |
| Oct 8, 2026 | 27.09 | 29.80 | 26.65 | 29.36 | 31.90K |
| Oct 7, 2026 | 26.74 | 27.95 | 26.72 | 26.72 | 12.70K |
| Oct 6, 2026 | 27.68 | 28.15 | 26.81 | 26.81 | 27.80K |
| Oct 5, 2026 | 29.00 | 29.78 | 28.00 | 28.10 | 22.10K |
| Oct 2, 2026 | 30.20 | 31.06 | 29.20 | 29.20 | 68.40K |
| Oct 1, 2026 | 31.99 | 31.99 | 29.20 | 30.68 | 20.90K |
| Sep 30, 2026 | 31.97 | 32.59 | 30.62 | 31.01 | 10.60K |
| Sep 29, 2026 | 28.70 | 32.00 | 26.45 | 31.17 | 21.80K |
| Sep 28, 2026 | 30.00 | 31.20 | 26.90 | 29.00 | 40.80K |
| Sep 25, 2026 | 30.40 | 31.00 | 29.98 | 31.00 | 10.30K |
| Sep 24, 2026 | 30.81 | 30.81 | 29.60 | 30.00 | 10.90K |
| Sep 23, 2026 | 31.01 | 31.01 | 29.02 | 30.15 | 7.60K |
| Sep 22, 2026 | 32.79 | 32.99 | 30.50 | 31.35 | 24.00K |
| Sep 21, 2026 | 29.46 | 31.00 | 28.54 | 31.00 | 13.60K |
| Sep 18, 2026 | 27.20 | 30.00 | 27.20 | 29.48 | 48.80K |
About IRulya Therapeutics
IRulya Therapeutics (QNCX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1662774.
QNCX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Luca Benatti | Director | Dec 29, 2025 |
| June Bray | Director | Jan 21, 2026 |
| David Lamond | Director | Jun 15, 2026 |
| Margaret Mcloughlin | Director | Jan 21, 2026 |
| Brigette Roberts | Chief Corp. Affairs Officer | Jun 11, 2026 |
| Christopher J. Senner | Director | Jun 15, 2026 |
| Dirk Thye | CEO and CMO | Jan 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Brendan Hannah | CBO, COO & CCO | Jan 23, 2026 |
| Brigette Roberts | Chief Corp. Affairs Officer | Jun 11, 2026 |
| Charles S. Ryan | President | Jan 23, 2026 |
| Dirk Thye | CEO and CMO | Jan 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 26, 2025 | Luca Benatti | Sale | 50,000 | $3.47 |
| Dec 26, 2025 | Luca Benatti | Sale | 50,000 | $3.47 |
| Dec 26, 2025 | Luca Benatti | Sale | 50,000 | $3.47 |
| Dec 26, 2025 | Luca Benatti | Sale | 50,000 | $3.47 |
QNCX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-83.98M | -1.68 | $-41.42M |
| Dec 31, 2024 | — | $-56.83M | -1.31 | $-31.90M |
| Dec 31, 2023 | — | $-31.39M | -0.84 | $-18.29M |
| Dec 31, 2022 | — | $-51.66M | -1.54 | $-44.04M |
| Dec 31, 2021 | — | $-89.94M | -3.03 | $-62.93M |
Latest balance sheet: total assets $124.00M, total liabilities $15.51M, cash $115.98M (as of Jun 30, 2026).
QNCX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $34.04 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $45.20 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $342.00 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $320.00 |
| May 13, 2025 | 8-K Item 2.02 (results) | $190.00 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $280.00 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $318.00 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| Jul 24, 2023 | 8-K Item 2.02 (results) | — |
| Jan 30, 2023 | 8-K Item 2.02 (results) | — |
| Aug 1, 2022 | 8-K Item 2.02 (results) | — |
| May 12, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on QNCX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.